Traws Pharma Inc. (NASDAQ: TRAW) on Wednesday shared interim data from an ongoing randomized, open-label Phase 2 with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor.

INNSBRUCK, Austria, Dec. 9, 2025 /PRNewswire/ -- As cyberattacks continue to challenge even the most resilient organisations, the need for clear, trustworthy, and openly documented security testing ...

US sales flat, store visits fell Margins hit by rising coffee prices, tariffs, investment costs China sales rise 2%, facing competition from local chains Oct 29 (Reuters) - Starbucks (SBUX.O), opens ...

9 September 2025, New York – Following a decade-long military build-up, global military spending hit a record high in 2024, soaring by more than nine per cent from 2023 and signaling a dangerous move ...

OpenAI is building new features within ChatGPT that would make it a direct competitor with workplace productivity suites like Google Workplace and Microsoft Office 365, The Information reported ...

Congressional Republicans approved President Donald Trump’s sweeping tax and spending cuts package, otherwise known as the “big, beautiful bill.” The House GOP ultimately passed the Senate’s ...

If you purchase an independently reviewed product or service through a link on our website, Rolling Stone may receive an affiliate commission. First, it was the ‘Wirkin’ — Walmart‘s now-infamous ...

Pew Research Center conducted this study to continue tracking news consumption and trust across a wide range of specific news sources. We last published similar reports in 2020 (based on a 2019 survey ...